Unknown PHASE2 INTERVENTIONAL 1-arm NCT03192735

Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Apatinib Combined With Oxaliplatin and Gimeracil and Oteracil Porassium Capsules Neoadjuvant Therapy for Locally Advanced Gastric Cance: A Multicentre, One-armed, Clinical Pilot Trial

Sponsor: Chang-Ming Huang, Prof.

Conditions Apatinib Combined Locally Advanced Gastric Cancer Neoadjuvant Therapy SOX

Interventions ApatinibMesylateTablets

Updated 7 times since 2017 Last updated: Feb 4, 2020 Started: Sep 1, 2017 Primary completion: Nov 11, 2019 Completion: Dec 11, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Apatinib Combined and Locally Advanced Gastric Cancer and is currently ongoing. Chang-Ming Huang, Prof. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jun 2018 — Mar 2020 [monthly]

Recruiting PHASE2
Jul 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang-Ming Huang, Prof.

Data source: Fujian Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fuzhou, China